Q4 2016 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$6.5B

Gross Profit

$3.4B52.2% margin

Operating Income

-$137M-2.1% margin

Net Income

-$973M-15.0% margin

EPS (Diluted)

$-0.96

QoQ Revenue Growth

+16.7%

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$1.1B

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$92.9B

Total Liabilities

$57.9B

Stockholders' Equity

$33.3B

Cash & Equivalents

$988M

Revenue Segments

Branded

$2.2B37%

Branded CNS

$1.2B21%

Branded C N S Copaxone

$1.0B17%

Branded Respiratory Products

$325M5%

Branded Oncology Products

$268M5%

Other Branded Products

$245M4%

Branded Oncology Treanda and Bendeka

$150M3%

Branded Respiratory Proair

$139M2%

Branded Womens Health Products

$122M2%

Branded Respiratory Qvar

$116M2%

Branded C N S Azilect

$88M1%

Branded C N S Nuvigil

$25M0%